Journey Medical (DERM)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	22.46 mm	22.46 mm	22.46 mm	22.46 mm	22.46 mm	22.46 mm
Cash burn (monthly)	483.67 k	190.67 k	964.67 k	1.57 mm	385.67 k	2.32 mm
Cash used (since last report)	2.07 mm	814.25 k	4.12 mm	6.69 mm	1.65 mm	9.92 mm
Cash remaining	20.40 mm	21.65 mm	18.34 mm	15.77 mm	20.81 mm	12.54 mm
Runway (months of cash)	42.2	113.5	19.0	10.1	54.0	5.4

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

DERM institutional ownership history Ownership history

58.3% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	38	34	+11.8%
Opened positions	10	12	-16.7%
Closed positions	6	11	-45.5%
Increased positions	7	6	+16.7%
Reduced positions	9	6	+50.0%

13F shares	Current	Prev Q	Change
Total value	9.30 bn	9.00 bn	+3.3%
Total shares	12.18 mm	12.19 mm	-0.1%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
FBIO Fortress Biotech	10.01 mm	$82.09 mm	0.0%
Vanguard	325.17 k	$1.84 bn	+4.8%
Cambridge Investment Research Advisors	314.45 k	$1.78 mm	+6.6%
Renaissance Technologies	268.20 k	$1.52 bn	+1.6%
AFG American Financial	180.00 k	$1.02 mm	0.0%
PVG Asset Management	167.55 k	$946.63 mm	NEW
Envestnet Asset Management	109.59 k	$619.16 mm	-16.7%
Geode Capital Management	108.44 k	$612.78 mm	+13.5%
Rosalind Advisors	105.92 k	$598.43 mm	-7.2%
Neuberger Berman	64.39 k	$363.83 mm	-5.7%

Largest transactions	Shares	Bought/sold	Change
PVG Asset Management	167.55 k	+167.55 k	NEW
Tang Capital Management	0.00	-148.32 k	EXIT
Acadian Asset Management	41.71 k	-52.69 k	-55.8%
BlackRock	52.62 k	+52.62 k	NEW
BLK BlackRock	0.00	-51.86 k	EXIT
Walleye Capital	23.10 k	-40.48 k	-63.7%
Envestnet Asset Management	109.59 k	-21.99 k	-16.7%
ORG Wealth Partners	19.52 k	+19.52 k	NEW
Cambridge Investment Research Advisors	314.45 k	+19.50 k	+6.6%
Vanguard	325.17 k	+14.92 k	+4.8%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

DERM insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
1 Aug 24	Joseph Benesch	Common Stock, $0.0001 par value	Sell	Dispose S	No	No	5.47	9,324	51.00 k	47,331
23 Jul 24	Joseph Benesch	Common Stock, $0.0001 par value	Sell	Dispose S	No	No	5.4	4,055	21.90 k	56,655
19 Jul 24	Michael Cooper Pearce	Common Stock, $0.0001 par value	Grant	Acquire A	No	No	0	30,000	0.00	30,000
8 Jul 24	Rosenwald Lindsay A MD	Common Stock, $0.0001 par value	Grant	Acquire A	No	No	0	9,728	0.00	153,973

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

12 Health Care Stocks Moving In Friday's Pre-Market Session

29 Nov 24

Journey Medical Q3 EPS $(0.12) Beats $(0.15) Estimate, Sales $14.63M Beat $14.39M Estimate

12 Nov 24

Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 20 percent. This is a 115 percent decrease over earnings of $0.80 per share from the

Press releases

From Benzinga Pro

Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

23 Jan 25

SCOTTSDALE, Ariz., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

14 Nov 24

Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or locally advanced cutaneous

Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

12 Nov 24

U.S. FDA approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults; launch expected in late Q1 or early Q2 of 2025 Total revenues